MarginsXMarginsX
Home › Markets › Health Care › CTMX

CytomX Therapeutics Inc. (CTMX)

CTMX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.99
-2.70% on the day
Market cap
$432.7M
Small cap
Revenue · 2025
$76.2M
-44.8% on 2024
Net income · 2025
-$17.4M
-22.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1501989/000119312526107146/0001193125-26-107146-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCTMX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001501989
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$76.2M
Net income-$17.4M
Operating income-$22.4M
Net margin-22.8%
Operating margin-29.3%
Revenue growth-44.8%
Cash$12.7M
Total assets$151.6M
P/E (computed)Net income was not positive
P/S (computed)5.7×

Warning signs

Cash runway
8.1 months
$34.0M cash at September 30, 2026
Share count, 1 year
+28.7%
2025-10-31 to 2026-10-31 · +225.4% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$1.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$34.0M cash; operating cash flow -$12.6M a quarter.Report 2026-09-30
Shares outstanding218,004,920 (2026-10-31); 169,435,395 a year earlier; 66,988,904 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-03-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Francisco, California, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.7M-$20.0M$16.6M$34.0MNo debt tags$14.0M10-Q 2026-11-05
Q2 2026
2026-06-30
$1.4M-$20.7M-$18.1M$17.2MNo debt tags$18.3M10-Q 2026-08-06
Q1 2026
2026-03-31
$10.3M-$18.2M-$25.5M$28.8MNo debt tags$35.5M10-Q 2026-05-07
Q4 2025
2025-12-31
$663K-$26.5M-$23.2M$12.7MNo debt tags$76.2M10-K 2026-03-16
Q3 2025
2025-09-30
$6.0M-$14.2M-$15.5M$34.2MNo debt tags$113.6M10-Q 2026-11-05
Q2 2025
2025-06-30
$18.7M-$154K-$15.8M$49.0MNo debt tags$141.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$50.9M$23.5M-$21.0M$47.6MNo debt tags$147.6M10-Q 2026-05-07
Q4 2024
2024-12-31
$38.1M$18.9M-$19.9M$38.1MNo debt tags$138.1M10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-18
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 801 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.8%
1 month-12.3%
3 months-39.1%
Year to date-52.1%
1 year-47.2%
From 52-week high-69.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BLSMBlossomHill Therapeutics Inc.$13.65-2.64%$433.9M
ASMBAssembly Biosciences Inc.$21.29+0.80%$436.0M
EOLSEvolus Inc.$6.63-4.74%$438.8M
AVTXAvalo Therapeutics Inc.$7.37-5.03%$426.2M
ARVNArvinas Inc.$6.77-0.73%$443.3M
MPLTMapLight Therapeutics Inc.$6.90-4.83%$446.9M
DMACDiaMedica Therapeutics Inc.$8.33-5.23%$449.5M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier